Cargando…

Barriers to gBRCA Testing in High-Risk HER2-Negative Early Breast Cancer

Despite the OlympiA trial demonstrating that early-stage, high-risk, HER2- germline BRCA1 and BRCA2 mutation (gBRCAm) positive breast cancer patients can benefit from PARPi in the adjuvant setting, the gBRCA testing rate in early-stage HR+/HER2− patients remains suboptimal compared to that in early-...

Descripción completa

Detalles Bibliográficos
Autores principales:	Foroughi, Olivia, Madraswala, Shaheen, Hayes, Jennifer, Glover, Kara, Lee, Liam, Chaki, Moumita, Redpath, Stella, Yu, Agnes Weixuan, Chiu, David, Amanti, Kristen Garner, Gustavsen, Gary
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10455724/ https://www.ncbi.nlm.nih.gov/pubmed/37623478 http://dx.doi.org/10.3390/jpm13081228

Ejemplares similares

All HER2-negative breast cancer patients need gBRCA testing: cost-effectiveness and clinical benefits
por: Wu, Huai-liang, et al.
Publicado: (2022)

Correction to: All HER2-negative breast cancer patients need gBRCA testing: cost-effectiveness and clinical benefits
por: Wu, Huai-liang, et al.
Publicado: (2023)

Stakeholders Perceptions of Barriers to Precision Medicine Adoption in the United States
por: Schroll, Monica M., et al.
Publicado: (2022)

Identification of biomarkers of response to preoperative talazoparib monotherapy in treatment naïve gBRCA+ breast cancers
por: Liu, Xuan, et al.
Publicado: (2022)

Dramatic, durable response to therapy in gBRCA2-mutated pancreas neuroendocrine carcinoma: opportunity and challenge
por: Keane, Fergus, et al.
Publicado: (2023)

A Quantitative Framework for Measuring Personalized Medicine Integration into US Healthcare Delivery Organizations
por: Agarwal, Arushi, et al.
Publicado: (2021)

Germinal BRCA1-2 pathogenic variants (gBRCA1-2pv) and pancreatic cancer: epidemiology of an Italian patient cohort
por: Peretti, U., et al.
Publicado: (2021)

Timely Genetic Testing and Therapy Management in Patients With gBRCA-Mutated Metastatic Breast Cancer Receiving Talazoparib
por: Martinez, Ashley, et al.
Publicado: (2022)

Association of gBRCA1/2 mutation locations with ovarian cancer risk in Japanese patients from the CHARLOTTE study
por: Yoshihara, Kosuke, et al.
Publicado: (2020)

What Causes Cancer in Women with a gBRCA Pathogenic Variant? Counselees’ Causal Attributions and Associations with Perceived Control
por: Kendel, Friederike, et al.
Publicado: (2022)

Chemotherapy toxicity and activity in patients with pancreatic ductal adenocarcinoma and germline BRCA1-2 pathogenic variants (gBRCA1-2pv): a multicenter survey
por: Orsi, G., et al.
Publicado: (2021)

Relevance of Platinum-free Interval and BRCA Reversion Mutations for Veliparib Monotherapy after Progression on Carboplatin/Paclitaxel for gBRCA Advanced Breast Cancer (BROCADE3 Crossover)
por: Puhalla, Shannon L., et al.
Publicado: (2021)

Genomic analysis of advanced breast cancer tumors from talazoparib-treated gBRCA1/2mut carriers in the ABRAZO study
por: Turner, Nicholas C., et al.
Publicado: (2023)

Physical activity and Mediterranean diet as potential modulators of osteoprotegerin and soluble RANKL in gBRCA1/2 mutation carriers: results of the lifestyle intervention pilot study LIBRE-1
por: Neirich, Leonie, et al.
Publicado: (2021)

DCIS in BRCA1 and BRCA2 mutation carriers: prevalence, phenotype, and expression of oncodrivers C-MET and HER3
por: Yang, Rachel L., et al.
Publicado: (2015)

The Breast Cancer Protooncogenes HER2, BRCA1 and BRCA2 and Their Regulation by the iNOS/NOS2 Axis
por: Lin, Katie, et al.
Publicado: (2022)

Beyond BRCA1 and BRCA2: Deleterious Variants in DNA Repair Pathway Genes in Italian Families with Breast/Ovarian and Pancreatic Cancers
por: Germani, Aldo, et al.
Publicado: (2020)

Gastric Cancer Risk and Pathogenesis in BRCA1 and BRCA2 Carriers
por: Buckley, Kole H., et al.
Publicado: (2022)

Prognostic significance of germline BRCA mutations in patients with HER2-POSITIVE breast cancer
por: Viansone, A., et al.
Publicado: (2022)

Comprehensive analysis of the molecular bases of OCA in Indians
por: Ray, Kunal, et al.
Publicado: (2010)

Neoadjuvant study of niraparib in patients with HER2-negative, BRCA-mutated, resectable breast cancer
por: Spring, Laura M., et al.
Publicado: (2022)

Exosomes containing miRNAs targeting HER2 synthesis and engineered to adhere to HER2 on tumor cells surface exhibit enhanced antitumor activity
por: Wang, Lei, et al.
Publicado: (2020)

BRCA locus-specific loss of heterozygosity in germline BRCA1 and BRCA2 carriers
por: Maxwell, Kara N., et al.
Publicado: (2017)

Rapid detection of copy number variations and point mutations in BRCA1/2 genes using a single workflow by ion semiconductor sequencing pipeline
por: Germani, Aldo, et al.
Publicado: (2018)

Impact of BRCA1 BRCT Domain Missense Substitutions on Phosphopeptide Recognition
por: Coquelle, Nicolas, et al.
Publicado: (2011)

BRCA1 Promoter Methylation and Expression - Associations with ER+, PR+ and HER2+ Subtypes of Breast Carcinoma
por: Kumar, Mohit, et al.
Publicado: (2017)

Adjuvant Olaparib for Germline BRCA Carriers With HER2-Negative Early Breast Cancer: Evidence and Controversies
por: Morganti, Stefania, et al.
Publicado: (2023)

Toxicity of (neo)adjuvant chemotherapy for BRCA1- and BRCA2-associated breast cancer
por: Drooger, Jan C., et al.
Publicado: (2016)

Real-world clinical outcomes of patients with BRCA-mutated, human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer: a CancerLinQ® study
por: Miller, Robert S., et al.
Publicado: (2022)

Determinants of Response to Talazoparib in Patients with HER2-Negative, Germline BRCA1/2-Mutated Breast Cancer
por: Blum, Joanne L., et al.
Publicado: (2022)

Author Correction: Neoadjuvant study of niraparib in patients with HER2-negative, BRCA-mutated, resectable breast cancer
por: Spring, Laura M., et al.
Publicado: (2022)

Development of the B cell cancer vaccine HER-vaxx for the treatment of her-2 expressing cancers
por: Ede, Nicholas J., et al.
Publicado: (2022)

BRCA Challenge: BRCA Exchange as a global resource for variants in BRCA1 and BRCA2
por: Cline, Melissa S., et al.
Publicado: (2018)

Perceived harms and protective behavioural strategies among khat chewers: a qualitative study in Jimma, Ethiopia
por: Olani, Amanti Baru, et al.
Publicado: (2023)

Prevalence of tumor BRCA1 and BRCA2 dysfunction in unselected patients with ovarian cancer
por: Kalachand, Roshni D., et al.
Publicado: (2020)

The role of novel poly (ADP-ribose) inhibitors in the treatment of locally advanced and metastatic Her-2/neu negative breast cancer with inherited germline BRCA1/2 mutations. A review of the literature
por: Pop, Lucian, et al.
Publicado: (2021)

Immunohistochemical Expression of BRCA1 Protein, ER, PR and Her2/neu in Breast Cancer: A Clinicopathological Study
por: Hussein, Israa A, et al.
Publicado: (2020)

Olaparib in hormone receptor-positive, HER2-negative metastatic breast cancer with a somatic BRCA2 mutation
por: Schwartzberg, Lee S., et al.
Publicado: (2021)

Mutational Analysis of BRCA1 and BRCA2 Genes in Breast Cancer Patients from Eastern Sicily
por: Stella, Stefania, et al.
Publicado: (2022)

Surgical Treatment of a Rare Isolated Bilateral Agenesis of Anterior and Posterior Cruciate Ligaments
por: Cerulli, G., et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_gprtlqp9okb48a7nl6vc9drj6i